Amgen to Release Q2 Earnings: What Investors Should Expect

Earnings Preview: Amgen Set to Announce Second-Quarter Results Biotech giant Amgen (NASDAQ: AMGN) is scheduled to release its Q2 earnings after the market closes tomorrow. Here's what investors should anticipate. Last quarter, Amgen surpassed analysts' revenue forecasts by 1.5%, posting $8.15 billion in revenue—a 9.4% increase compared to the previous year. The quarter was considered satisfactory, with earnings per share (EPS) exceeding expectations, while the full-year revenue guidance aligned with analyst estimates. Looking ahead, market forecasts suggest that Amgen's revenue will rise approximately 6.6% year-over-year to $8.94 billion, a slowdown from last year's 20.1% growth in the same period. Adjusted earnings are projected to be around $5.28 per share. Over the past month, analysts have largely maintained their previous estimates, indicating confidence in the company's outlook heading into earnings. However, it's worth noting that Amgen has missed Wall Street revenue estimates twice in the past two years. Comparing to industry peers, some have already reported their Q2 results, offering insights into potential outcomes. Biogen achieved a 7.3% revenue increase year-over-...